Literature DB >> 25977340

Classifying Cancers Based on T-cell Infiltration and PD-L1.

Michele W L Teng1, Shin Foong Ngiow2, Antoni Ribas3, Mark J Smyth4.   

Abstract

Cancer immunotherapy may become a major treatment backbone in many cancers over the next decade. There are numerous immune cell types found in cancers and many components of an immune reaction to cancer. Thus, the tumor has many strategies to evade an immune response. It has been proposed that four different types of tumor microenvironment exist based on the presence or absence of tumor-infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression. We review this stratification and the latest in a series of results that shed light on new approaches for rationally designing ideal combination cancer therapies based on tumor immunology. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25977340      PMCID: PMC4452411          DOI: 10.1158/0008-5472.CAN-15-0255

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Radiation and immunotherapy: a synergistic combination.

Authors:  Anusha Kalbasi; Carl H June; Naomi Haas; Neha Vapiwala
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

Review 2.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

Review 3.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

4.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

Authors:  Robert J Johnston; Laetitia Comps-Agrar; Jason Hackney; Xin Yu; Mahrukh Huseni; Yagai Yang; Summer Park; Vincent Javinal; Henry Chiu; Bryan Irving; Dan L Eaton; Jane L Grogan
Journal:  Cancer Cell       Date:  2014-11-26       Impact factor: 31.743

5.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

6.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection.

Authors:  Alison Crawford; Jill M Angelosanto; Charlly Kao; Travis A Doering; Pamela M Odorizzi; Burton E Barnett; E John Wherry
Journal:  Immunity       Date:  2014-02-13       Impact factor: 31.745

9.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

Authors:  Gabriela Bindea; Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Maximilian Waldner; Anna C Obenauf; Helen Angell; Tessa Fredriksen; Lucie Lafontaine; Anne Berger; Patrick Bruneval; Wolf Herman Fridman; Christoph Becker; Franck Pagès; Michael R Speicher; Zlatko Trajanoski; Jérôme Galon
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

Review 10.  Immune modulation in cancer with antibodies.

Authors:  David B Page; Michael A Postow; Margaret K Callahan; James P Allison; Jedd D Wolchok
Journal:  Annu Rev Med       Date:  2013-10-30       Impact factor: 13.739

View more
  516 in total

Review 1.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:  Antoni Ribas
Journal:  Cancer Discov       Date:  2015-08-13       Impact factor: 39.397

2.  Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.

Authors:  Qian Zhu; Mu-Yan Cai; Chang-Long Chen; Hao Hu; Huan-Xin Lin; Min Li; De-Sheng Weng; Jing-Jing Zhao; Ling Guo; Jian-Chuan Xia
Journal:  Oncoimmunology       Date:  2017-04-27       Impact factor: 8.110

3.  Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy.

Authors:  Panagiotis Balermpas; Daniel Martin; Ulrike Wieland; Margret Rave-Fränk; Klaus Strebhardt; Claus Rödel; Emmanouil Fokas; Franz Rödel
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

4.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

5.  PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.

Authors:  Melanie Boxberg; Katja Steiger; Ulrich Lenze; Hans Rechl; Rüdiger von Eisenhart-Rothe; Klaus Wörtler; Wilko Weichert; Rupert Langer; Katja Specht
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

6.  Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

Authors:  Xiaofang Xing; Jianping Guo; Guangyu Ding; Bo Li; Bin Dong; Qin Feng; Shen Li; Jian Zhang; Xiaomin Ying; Xiaojing Cheng; Ting Guo; Hong Du; Ying Hu; Tao Zhou; Xiaohong Wang; Lin Li; Qingda Li; Meng Xie; Liting Li; Xiangyu Gao; Fei Shan; Ziyu Li; Xianzi Wen; Jiping Wang; Jiafu Ji
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

7.  TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Authors:  V Cervera-Carrascon; M Siurala; J M Santos; R Havunen; S Tähtinen; P Karell; S Sorsa; A Kanerva; A Hemminki
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

Review 8.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

9.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

10.  PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.

Authors:  Marius Ilie; Alexander T Falk; Catherine Butori; Emmanuel Chamorey; Christelle Bonnetaud; Elodie Long; Sandra Lassalle; Katia Zahaf; Nicolas Vénissac; Jérôme Mouroux; Charlotte Cohen; Elisabeth Brambilla; Charles Hugo Marquette; Véronique Hofman; Paul Hofman
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.